

## **SCYNEXIS Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 26-Apr-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 13

Product Portfolio Financials..... 17

Product Portfolio Drugs..... 18

[Return to Table of Contents](#)

# SCYNEXIS Inc

## COMPANY OVERVIEW

Company Name	SCYNEXIS Inc
Parent Company Name	SCYNEXIS Inc
Website	<a href="http://www.scynexis.com/">http://www.scynexis.com/</a>
Country	US
Number of Drugs in Active Development	8
Number of Inactive Drugs	7
Number of Patents as Owner	21
Number of Patents as Third Party	0
Number of Deals	24
Key Indications	Fungal infection, Trypanosoma cruzi infection, Trypanosoma brucei infection, Candida infection, Leishmania donovani infection, Parasitic infection, Hepatitis C virus infection, HIV infection, Alzheimers disease, Amoeba infection, Aspergillus infection, Asthma, Autoimmune disease, Cryptococcus infection, Dengue virus infection, Glomerulonephritis, Hepatitis B virus infection, Influenza virus infection, Insulin dependent diabetes, Ischemia, Keratitis, Meningitis, Pneumonia, Psoriasis, Reperfusion injury, Respiratory syncytial virus infection, Toxoplasma infection, Trichomonas
Key Target-based Actions	Peptidylprolyl isomerase inhibitor, 1,3 beta glucan synthase inhibitor, Calcineurin inhibitor, Peptidyl-prolyl cis-trans isomerase D inhibitor, Glucan synthase inhibitor, IL-2 antagonist, Interleukin-29 ligand
Key Technologies	Small molecule therapeutic, Biological therapeutic, Oral formulation, Peptide, Capsule formulation, Intravenous formulation, Natural product, Assay, Chemical isolation, Fermentation synthesis, Stereochemical

## COMPANY PROFILE

### SUMMARY

SCYNEXIS (formerly SCYNEXIS Chemistry & Automation) is a chemistry- focused drug discovery company. Formed in 2000 as an independent spin-off of Aventis CropScience, SCYNEXIS utilizes its proprietary MEDCHEM-FACTORY to optimize lead molecules for candidate selection and deliver drug pipeline solutions to pharmaceutical partners from early discovery to phase II.

### COMPANY LOCATION

In December 2009, the company's process chemistry, analytical and manufacturing facilities were found to be in full compliance with cGMP manufacturing and analytical regulations following an FDA inspection.

### LICENSING AGREEMENTS

In May 2009, SCYNEXIS granted Medicines for Malaria Venture (MMV) access to its HEOS drug discovery platform.

In December 2008, SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi) extended their research alliance for an added three years. In November 2007, SCYNEXIS and DNDi established a drug research alliance to discover therapies for sleeping sickness.

In December 2006, SCYNEXIS Chemistry & Automation and Merck & Co formed a multi-year research collaboration to discover and develop new cancer drugs. SCYNEXIS would produce highly-targeted compound libraries and use rapid lead optimization techniques to select drug candidates. In October 2009, SCYNEXIS received a payment for a preclinical milestone.

By December 2005, SCYNEXIS and Merial were collaborating on the research of novel compounds for animal health needs. In November 2009, SCYNEXIS received a milestone payment from Merial in its multi-year research collaboration.

[Return to Table of Contents](#)



In October 2005, SCYNEXIS agreed to provide medicinal and analytical chemistry services for Teijin Pharma's drug development programs.

In April 2004, Norak Biosciences Inc and SCYNEXIS entered into a R&D collaboration. Norak transferred certain active compounds and chemical structures from its Transflour screening program against novel desensitization targets to SCYNEXIS. Norak was to gain access to a SCYNEXIS research unit, which included medicinal chemistry technology and expertise. Norak was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services.

In November 2002, SCYNEXIS entered into a research collaboration with F Hoffmann-La Roche Ltd to discover and develop novel compounds for the CNS, and metabolic diseases. The transaction would include access by Roche to the SCYNEXIS MEDCHEM-FACTORY technology and HEOS Hit Explorer Operating System software, thus accelerating the identification of novel leads against Roche's drug targets by producing large, focused, high-purity compound libraries and then utilizing rapid lead optimization to identify clinical candidates. Specific financial terms were not disclosed. However, Roche was to receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services. In September 2003, this collaboration was extended.

In June 2002, SCYNEXIS entered into a multiyear research collaboration with Merck & Co Inc to discover and develop novel anti-infective compounds. Utilizing its proprietary MEDCHEM-FACTORY technology, SCYNEXIS was to accelerate the identification of novel drugs against Merck's screening targets by producing large, highly targeted, high-purity compound libraries. Merck was to receive exclusive worldwide rights to products developed through the collaboration. SCYNEXIS was to receive milestone payments and royalties on sales. In July 2003, this research collaboration was expanded. In January 2007, SCYNEXIS received a \$1 million payment from Merck & Co for meeting preclinical milestones under the companies' 2002 collaboration to develop antifungal agents. In December 2009, SCYNEXIS achieved a third milestone in its collaboration with Merck & Co to develop antifungals. The milestone was triggered by the initiation of clinical development for a compound generated under the collaboration. Under the terms of the original agreement, SCYNEXIS would receive milestones and double-digit percentage royalties.

In December 2001, Plexxikon Inc signed an agreement with SCYNEXIS, under the terms of which Plexxikon will access SCYNEXIS' proprietary MEDCHEM-FACTORY technology in order to accelerate its chemistry programs.

In February 2001, SCYNEXIS formed an alliance with two additional specialized research companies, Piedmont Research Center and Biotechnics Inc, to enhance its ability to quickly identify and bring forward the development of promising drug candidates.

## FINANCIAL

In April 2015, the company initiated an underwritten public offering of shares of its common stock to raise a gross proceeds of up to \$30 million. At that time, a 30-day option was granted to the underwriters for the purchase of an additional \$4.5 million of shares. Later that month, the company priced the offering of 4,675,324 shares at \$7.70 per share, with underwriters granted a 30-day option to purchase up to 701,298 additional shares.

By June 2014, SCYNEXIS had repayed a \$15 million credit facility.

In May 2014, the company priced its IPO of 6,200,000 shares of its common stock at \$10 per share. The underwriters were also granted a 30-day over-allotment option to purchase up to an additional 930,000 shares of common stock. In June 2014, the company raised net proceeds of \$40 million from the completed offering.

In March 2014, the company announced a initial public offering of 4,230,800 shares of its common stock priced between \$12.00 and \$14.00 per share. The underwriters were to be granted a 30-day option to purchase additional 634,620 shares of the common stock. At that time, the company filed an application to list the shares under the ticker symbol "SCYX" on the NASDAQ Global Market. In May 2014, the company's shares began trading on the NASDAQ Global Market.

In March 2008, SCYNEXIS completed a \$13.5 million Series C2 financing.

## COMPANY FINANCIALS

### SHARE INFORMATION

Close Price (USD)	9.47
Change (USD)	-0.52 (-5.21%)

[Return to Table of Contents](#)



<b>Previous Close Price (USD)</b>	9.99
<b>Volume</b>	78,434
<b>52-Week High (USD)</b>	15.00
<b>52-Week Low (USD)</b>	5.10
<b>Date</b>	24-Apr-2015
<b>Exchange</b>	NASDAQ(COMPOSITE)
<b>Current Number of Shares Outstanding</b>	8,512,103
<b>Current Market Capitalization</b>	80,609,615
<b>EPS (Date Reported)</b>	-0.74762

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Nothias (Jean-Yves)	Individual Investor	United States	295,077	2.24	0	0	31-Jan-2015


[Return to Table of Contents](#)



Principal SmallCap Blend Fund	Mutual Fund	United States	68,920	0.52	4,229	0.07	31-Mar-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	61,400	0.47	31,100	1.03	31-Mar-2015
Kirby (Pamela J)	Individual Investor	United States	25,490	0.19	0	0	31-Jan-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	25,850	0.2	0	0	28-Feb-2015
Ribeill (Yves J)	Individual Investor	United States	19,165	0.15	1,000	0.06	31-Jan-2015
Cadence Capital Management, LLC	Investment Advisor	United States	14,758	0.11	14,758	1	28-Feb-2015
AMG Managers Cadence Emerging Companies Fund	Mutual Fund	United States	14,758	0.11	14,758	1	28-Feb-2015
Langlois (Patrick J)	Individual Investor	United States	10,503	0.08	0	0	31-Jan-2015
Osborne (Charles F Jr)	Individual Investor	United States	9,366	0.07	416	0.05	31-Jan-2015
Principal Variable Contract SmallCap Blend Account	Mutual Fund	United States	8,340	0.06	135	0.02	31-Mar-2015
Arthaud (Laurent)	Individual Investor	United States	5,242	0.04	0	0	31-Jan-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	1,044	0.01	0	0	28-Feb-2015
Vanguard US Equity Index Fund	Mutual Fund	United States	1,000	0.01	1,000	1	28-Feb-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	500	0	0	0	28-Feb-2015

[Return to Table of Contents](#)

FINANCIAL PERFORMANCE



	2012	2013	2014		
Sales (USD M)	16.837	16.857	19.024		
Operating Income (USD M)	-11.196	-8.192	-12.277		
Net Income (USD M)	-11.477	-30.461	-4.234		

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	5.297	-3.076	-3.075
2014 Q3	4.38	-3.804	-3.804
2014 Q2	4.642	-3.616	-5.326
2014 Q1	4.705	-1.781	-1.221
2013 Q3	4.163	-2.014	-3.96
2013 Q2	4.226	-2.088	-2.703
2013 Q1	4.795	-1.598	-2.069

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	2.385	1.402	32.243		
Inventories - Total	0	0	0		
Current Assets - Total	5.224	2.953	34.736		
Property, Plant And Equipment - Net	6.284	5.401	4.835		
Other Assets - Total	0.61	4.033	0.101		
Total Assets	12.118	12.387	39.672		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	1.018	1.932	0.855		
Short Term Debt & Current Portion Of Long Term Debt	11.444	15	0		
Current Liabilities - Total	14.231	18.477	3.801		
Long Term Debt	15	0	0		
Other Liabilities	0.683	12.237	0		
Total Liabilities	31.447	33.339	6.241		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	46.086	87.157	0		
Common Stock	0.007	0.007	0.008		
Treasury Stock		0	0		
Total Liabilities & Shareholders' Equity	12.118	12.387	39.672		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-2.26	-2.2	-2.2
31-Dec-2016	-2.43	-2.38	-2.38
31-Dec-2017	-2.72	-2.86	-2.86

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-20.7	17.63
31-Dec-2016			-30.15	17.77
31-Dec-2017			-37.9	19.15

[Return to Table of Contents](#)




## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	8	5	13
Inflammatory disease	0	5	5
Gastrointestinal disease	0	4	4
Cardiovascular disease	0	1	1
Metabolic disorder	0	1	1
Neurological disease	0	1	1
Injury	0	1	1
Musculoskeletal disease	0	1	1
Endocrine disease	0	1	1
Ocular disease	0	1	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	6
Suspended	1
Discontinued	1
No Development Reported	6

[Return to Table of Contents](#)

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	3	0	1	0	4
Technology - Other Proprietary	5	0	0	0	5
Drug - Funding	2	0	0	0	2
Drug - Early Research/Development	1	0	2	0	3
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Development Services	6	0	0	0	6
Technology - Target Validation	0	1	0	1	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	4
Gastrointestinal disease	0	3
Inflammatory disease	0	3

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	2
Phase 1	0	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	1	0	1

[Return to Table of Contents](#)



Gastrointestinal disease	13	0	13
Genitourinary disease	1	0	1
Degeneration	1	0	1
Immune disorder	1	0	1
Ocular disease	2	0	2
Metabolic disorder	1	0	1
Neurological disease	2	0	2
Respiratory disease	3	0	3
Infectious disease	21	0	21
Injury	1	0	1
Inflammatory disease	16	0	16
Dermatological disease	1	0	1


\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2019



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### SCY-078

<b>Drug Name</b>	SCY-078
<b>Key Synonyms</b>	
<b>Originator Company</b>	Merck & Co Inc
<b>Active Companies</b>	R-Pharm, SCYNEXIS Inc
<b>Inactive Companies</b>	Merck & Co Inc
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Candida infection, Fungal infection
<b>Target-based Actions</b>	1,3 beta glucan synthase inhibitor
<b>Other Actions</b>	Glucan synthesis inhibitor, Fungicide
<b>Technologies</b>	Natural product, Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	23-Apr-2015

### SCYX-7158

<b>Drug Name</b>	SCYX-7158
<b>Key Synonyms</b>	
<b>Originator Company</b>	SCYNEXIS Inc
<b>Active Companies</b>	SCYNEXIS Inc, Drugs for Neglected Diseases Initiative, Anacor Pharmaceuticals Inc, Pace University
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Trypanosoma cruzi infection, Trypanosoma brucei infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic, Unspecified drug target
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	30-Jan-2015

[Return to Table of Contents](#)

### oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi

<b>Drug Name</b>	oxaborole series (visceral leishmaniasis/Chagas disease), Anacor Pharmaceuticals/DNDi
<b>Key Synonyms</b>	
<b>Originator Company</b>	Anacor Pharmaceuticals Inc
<b>Active Companies</b>	London School of Hygiene and Tropical Medicine, SCYNEXIS Inc, Anacor Pharmaceuticals Inc, University of Antwerp, Drugs for Neglected Diseases Initiative
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Leishmania donovani infection, Trypanosoma cruzi infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic, Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	02-Sep-2014

### serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS

<b>Drug Name</b>	serine hydrolase inhibitors (viral/parasitic infections), Abide/SCYNEXIS
<b>Key Synonyms</b>	
<b>Originator Company</b>	Abide Therapeutics Inc
<b>Active Companies</b>	SCYNEXIS Inc, Abide Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Parasitic infection
<b>Target-based Actions</b>	Hydrolase inhibitor
<b>Other Actions</b>	Antiparasitic, Antiviral
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	15-Dec-2014

[Return to Table of Contents](#)

### SCY-078 (intravenous, antifungal), SCYNEXIS

<b>Drug Name</b>	SCY-078 (intravenous, antifungal), SCYNEXIS
<b>Key Synonyms</b>	
<b>Originator Company</b>	SCYNEXIS Inc
<b>Active Companies</b>	SCYNEXIS Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Fungal infection
<b>Target-based Actions</b>	1,3 beta glucan synthase inhibitor
<b>Other Actions</b>	Glucan synthesis inhibitor, Fungicide
<b>Technologies</b>	Natural product, Intravenous formulation, Biological therapeutic
<b>Last Change Date</b>	31-Mar-2015

### Oxachagas

<b>Drug Name</b>	Oxachagas
<b>Key Synonyms</b>	
<b>Originator Company</b>	Drugs for Neglected Diseases Initiative
<b>Active Companies</b>	Drugs for Neglected Diseases Initiative, Murdoch University, SCYNEXIS Inc, University of Antwerp, Anacor Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Trypanosoma cruzi infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Antiparasitic
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	03-Sep-2014

[Return to Table of Contents](#)

### ciclosporin analogs (fungal infection), SCYNEXIS

<b>Drug Name</b>	ciclosporin analogs (fungal infection), SCYNEXIS
<b>Key Synonyms</b>	
<b>Originator Company</b>	SCYNEXIS Inc
<b>Active Companies</b>	SCYNEXIS Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Fungal infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Fungicide
<b>Technologies</b>	Biological therapeutic, Peptide
<b>Last Change Date</b>	17-Feb-2015

### oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS

<b>Drug Name</b>	oxaborole backup compounds (human African trypanosomiasis), DNDi/Anacor/Pace University/SCYNEXIS
<b>Key Synonyms</b>	
<b>Originator Company</b>	Drugs for Neglected Diseases Initiative
<b>Active Companies</b>	Anacor Pharmaceuticals Inc, Drugs for Neglected Diseases Initiative, Pace University, SCYNEXIS Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Suspended
<b>Active Indications</b>	Trypanosoma brucei infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic, Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	05-Sep-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

